Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to Issue Quarterly Dividend of $0.24

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Friday, May 22nd. Stockholders of record on Thursday, June 25th will be given a dividend of 0.24 per share by the medical equipment provider on Friday, July 31st. This represents a c) dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th.

Zimmer Biomet has a payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Zimmer Biomet to earn $8.91 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Stock Down 0.8%

Shares of NYSE:ZBH opened at $87.29 on Tuesday. The firm has a 50 day simple moving average of $87.13 and a 200 day simple moving average of $90.05. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The company has a market cap of $16.89 billion, a PE ratio of 22.67, a price-to-earnings-growth ratio of 2.59 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the previous year, the company posted $1.81 EPS. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, research analysts expect that Zimmer Biomet will post 8.49 earnings per share for the current year.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays decreased their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Stifel Nicolaus lowered their target price on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research note on Wednesday, April 29th. Citigroup dropped their target price on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, Truist Financial reissued a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $102.70.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.